TrialsgrambetaRCTs are beautiful

BRIM-3

2011

Vemurafenib in BRAF V600E-Mutant Metastatic Melanoma

In 675 patients with BRAF V600E-mutant unresectable or metastatic melanoma, vemurafenib improved overall survival compared with dacarbazine.

Result

Efficacy: Co-primary: overall survival and progression-free survival (OS interim analysis)HR 0.37

Below 1 favours vemurafenib, above 1 favours dacarbazine.

Also reported: PFS 5.3 vs 1.6 months (HR 0.26); ORR 48% vs 5%.

Original publication
Subtopic
BRAF-mutant melanoma
Design
Open-label RCT
Relevance
Supporting: context rather than must-know.
Source
Chapman PB, et al. N Engl J Med. 2011;364(26):2507-2516.doi 10.1056/NEJMoa1103782

Discussion & critique

First BRAF inhibitor: proved the precision-oncology principle in melanoma. Resistance emerges quickly; BRAF+MEK combinations (COMBI-d/v) are now preferred.